Supportive Care

CMV Prophylaxis
Adult Allogeneic Stem Cell Transplant Recipients Aged ≥ 18 Years-Old

Study Number: CMX001-301
Protocol Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group,Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMVseropositive (R+) Hematopoietic Stem Cell Transplant Recipients
Status: Open
Principal Investigator: James Essell, M.D.

To learn more, please call Blood Cancer Center at The Jewish Hospital – Mercy Health at 513-686-5482 or complete the Contact Us Form.